Immunotherapy in the Treatment of Biliary Tract Cancer: The Future?

Clicks: 114
ID: 282929
2022
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Biliary tract cancer is known for its dismal prognosis, both due to late diagnosis as well as to the short width span of therapeutic options available. Although much more common in Asian countries, the number of patients with these tumours has been rising in European and American countries, mainly due to the increased rates of chronic hepatic diseases. Currently the only curative treatment revolves around surgical resection, although only possible in roughly 10-15% of patients. First line systemic therapies include chemotherapy with gemcitabine and cisplatin, unfortunately with also poor results with a 5-year survival rate of only 10-20%. With this in mind, the need for other therapeutic options has been proved, with the rising popularity of immunotherapy leading to several studies analysing the use of immune checkpoint inhibitors in the treatment of patients with biliary tract cancer.
Reference Key
dl2022immunotherapy Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors DL, Russo
Journal Gastroenterology & Hepatology International Journal
Year 2022
DOI
10.23880/ghij-16000187
URL
https://doi.org/10.23880/ghij-16000187
Keywords
immunotherapy treatment tract biliary cancer: future?

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.